Eisai Cuts US Leqembi Sales Forecast But Japan, China Exceed Expectations
Infusion Center Access Becomes Bottleneck
Eisai/Biogen’s Alzheimer’s disease medicine Leqembi has been a challenge to launch, but while access to pre-treatment testing has improved, infusion center capacity is impacting US sales.
